- Home
- PBT vs UPB Comparison
PBT vs UPB Comparison
Compare PBT & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- UPB
- Stock Information
- Founded
- PBT 1980
- UPB 2021
- Country
- PBT United States
- UPB United States
- Employees
- PBT N/A
- UPB N/A
- Industry
- PBT Oil & Gas Production
- UPB
- Sector
- PBT Energy
- UPB
- Exchange
- PBT Nasdaq
- UPB NYSE
- Market Cap
- PBT 562.6M
- UPB 521.3M
- IPO Year
- PBT N/A
- UPB 2024
- Fundamental
- Price
- PBT $12.05
- UPB $10.89
- Analyst Decision
- PBT
- UPB Strong Buy
- Analyst Count
- PBT 0
- UPB 4
- Target Price
- PBT N/A
- UPB $56.50
- AVG Volume (30 Days)
- PBT 312.0K
- UPB 411.4K
- Earning Date
- PBT 01-01-0001
- UPB 08-14-2025
- Dividend Yield
- PBT 4.53%
- UPB N/A
- EPS Growth
- PBT N/A
- UPB N/A
- EPS
- PBT 0.48
- UPB N/A
- Revenue
- PBT $24,140,674.00
- UPB $2,296,000.00
- Revenue This Year
- PBT N/A
- UPB N/A
- Revenue Next Year
- PBT N/A
- UPB N/A
- P/E Ratio
- PBT $25.13
- UPB N/A
- Revenue Growth
- PBT N/A
- UPB N/A
- 52 Week Low
- PBT $8.01
- UPB $5.14
- 52 Week High
- PBT $14.26
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- PBT 69.83
- UPB N/A
- Support Level
- PBT $11.92
- UPB N/A
- Resistance Level
- PBT $12.34
- UPB N/A
- Average True Range (ATR)
- PBT 0.31
- UPB 0.00
- MACD
- PBT 0.02
- UPB 0.00
- Stochastic Oscillator
- PBT 79.43
- UPB 0.00
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.